Dipòsit Digital de la Universitat de Barcelona
El Dipòsit Digital de la Universitat de Barcelona és el repositori institucional que conté en format digital els materials derivats de l'activitat docent, investigadora i institucional de la comunitat universitària.
Enviaments recents
Informe“L’habitatge DE luxe” o “l’habitatge ÉS un luxe”? Anàlisi social de la presència de grans inversors immobiliaris a la dreta de l’Eixample de Barcelona
(Universitat de Barcelona, 2025-09-05) Simó i Solsona, Montse; López Villanueva, Cristina; Cano-Hila, Ana Belén; Berrens, Karla; Romero Fernández, Ana
L’objectiu d’aquest document és donar compte del projecte de recerca “L’habitatge DE luxe” o “l’habitatge ÉS un luxe”? Anàlisi social de la presència de grans inversors immobiliaris a la dreta de l’Eixample de Barcelona, finançat per la Càtedra Barcelona Estudis d’Habitatge per les Beques 2024.
L’objectiu de la recerca ha estat analitzar l’impacte del creixent estoc de l’habitatge de luxe sobre les dinàmiques habitacionals, socials i urbanes al barri de la Dreta de l’Eixample amb la finalitat de donar resposta, de manera col·laborativa, a la demanda expressada per l'Associació de Veïns de la Dreta de l’Eixample. Aquesta ha estat duta a terme des de maig de 2024 fins al juliol de 2025 pel següent equip de treball: Montserrat Simó Solsona, Cristina López Villanueva, Ana Belén Cano Hila, Karla Berrens i Ana Romero Fernández, totes investigadores del Departament de Sociologia de la Universitat de Barcelona.
La pregunta de recerca que guia aquest projecte ha estat: Quins són els impactes derivats de la presència de promocions immobiliàries d’habitatge de luxe a la Dreta de l’eixample de Barcelona? La Dreta de l’Eixample segueix la mateixa tendència supergentrificadora que altres ciutats com Nova York o Londres? Què és allò que el singularitza?
L’estructura d’aquest document és seguit a la introducció, per després explicar els objectius tant generals i específics de la recerca i el seu assoliment. Posteriorment hi ha l’apartat de disseny de la recerca on es dona compte de la metodologia utilitzada amb les tècniques tant de recollida com d’anàlisi de la informació. El segueix l’apartat de resultats i d’activitats realitzades per cloure amb línies futures d’investigació i referències utilitzades.
ArticleRisk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials
(Oxford University Press (OUP), 2026-02-02) Y Hsue, Priscilla; Waters, Laura; Orkin, Chloe; Tiraboschi, Juan Manuel; Avihingsanon, Anchalee; Marongiu, Andrea; S Whiteman, Andrew; Tian, Yuan; M Nielson, Carrie; Aizen, Keith; Cohen, Calvin; T Hindman, Jason; K Rockstroh, Jürgen
Background People with HIV have a greater risk of cardiovascular disease than the general population. Current literature suggests that some ARTs may exacerbate this risk.Objectives To estimate the risk of hypertension in treatment-na & iuml;ve people with HIV receiving integrase strand transfer inhibitor (INSTI)/tenofovir alafenamide (TAF) or INSTI/non-TAF versus NNRTI/non-TAF regimens.Methods Post hoc pooled analysis evaluating data from US participants in five Phase 3 randomized studies. Adjusted prevalence of Stage 1 and 2 hypertension (American College of Cardiology/American Heart Association criteria) and conditional odds of higher blood pressure ratios were estimated using proportional odds mixed-effect regression through 108 weeks after ART initiation. Time to incident hypertension through 96 weeks was modelled using Cox proportional-hazards regression.Results In total, 2411 participants were included (528, 749 and 1134 received NNRTI/non-TAF, INSTI/non-TAF and INSTI/TAF regimens, respectively). Nearly half of participants had hypertension (Stage >= 1) at baseline. The Week 96 adjusted estimates of risk of hypertension (95% CI) were 1.06 (0.99, 1.13) and 1.12 (0.98, 1.27) for Stages >= 1 and >= 2 hypertension, respectively, for NNRTI/non-TAF versus INSTI/non-TAF, and 1.01 (0.95, 1.08) and 1.02 (0.91, 1.17) for Stages >= 1 and >= 2 hypertension, respectively, for NNRTI/non-TAF versus INSTI/TAF. There were no significant differences in conditional odds of high blood pressure between treatment groups. No significant differences were identified in time to incident composite hypertension for INSTI/non-TAF and INSTI/TAF versus NNRTI/non-TAF regimens; estimated hazard ratios (approximate 95% CI) were 0.88 (0.66, 1.17) and 0.98 (0.75, 1.28), respectively.Conclusions Results suggest the risk of hypertension is not significantly different across INSTI/TAF, INSTI/non-TAF and NNRTI/non-TAF regimens.
ArticleImmunotherapy and tyrosine kinase inhibitors in chordoma: a real-world data study from a European Reference Network on Rare Adult Solid Cancers member center
(Frontiers Media SA, 2026-02-03) Balsa, Mario; Torrent, Francesc; Pérez, Diana; Ruiz, Alejandro; Viñals, Joan Maria; Pablos, Oscar; Fontalva, Maria; Portabella, Federico; Lozano, Alicia; González-viguera, Javier; Narváez, Jose Antonio; Hernández, Javier; Sardiñas, Juan Carlos; Sanjuan, Xavier; Ippoliti, Gianni; Comabella, Ma Rosa; Sala, Rosó; García Del Muro, Xavier; Jiménez, Laura; Martin-liberal, Juan
Introduction Chordoma is a rare malignant tumor originating in the notochord characterized by slow progression but frequent recurrences. Systemic treatment for this condition is not well defined. This study aimed to describe real-world clinical practice patterns of systemic therapy and its outcomes in patients with advanced chordoma treated at a sarcoma referral center member of the European Reference Network on Rare Adult Solid Cancers (EURACAN).Methods Consecutive adult patients with histologically confirmed chordoma, diagnosed between 2005 and 2024, who received tyrosine kinase inhibitors (TKI) or immune checkpoint inhibitors (ICI), were retrospectively reviewed. Demographic, clinicopathological, and treatment data were collected from institutional databases. Responses were radiologically assessed according to RECIST criteria by sarcoma radiologists as part of routine clinical care. Data were collected up to December 31, 2024.Results A total of 13 patients (median age 62 years) were identified. All had undergone surgery, and more than half received adjuvant radiation therapy. Most patients (n=10, 76.9%) received systemic therapy with imatinib as first-line treatment, while a minority (n=2, 15.4%) received ICIs as first-line therapy. Several patients received multiple lines of treatment, including sequential exposure to TKI and ICI. Objective responses were observed in 2 of 5 patients in the TKI-only subgroup (40.0%) and 4 of 8 patients in the ICI-exposed subgroup (50.0%), all of which were partial responses, with prolonged disease stabilization being the a common outcome. The median progression-free survival (PFS) for the entire cohort was 12.3 months, and the median overall survival (OS) was 149.8 months. The median PFS and median OS in the TKI-only subgroup were 7.4 and 113.5 months, respectively, whereas they were 12.7 and 151.6 months in the ICI-exposed subgroup, respectively. Subgroup results are descriptive, exploratory, and hypothesis-generating due to the small sample size.Conclusion Our results indicate that systemic therapy can provide durable disease control in selected patients with chordoma. TKI are commonly used and may provide good responses while ICIs show potential activity in selected patients but await confirmation in robust clinical trials. These real-world data reinforce the need for prospective, multicenter studies to optimize treatment sequencing and patient selection in this rare malignancy.
Article
Early neurological deterioration before endovascular treatment in patients with mild stroke. MINORCAT-END-EVT study
(Elsevier BV, 2026-02-11) Font, Maria Àngels; García-sánchez, Sonia María; Mengual, Juan José; Avellaneda, Carla; Boned, Sandra; Doncel-moriano, Antonio; Urra, Xabier; Camps-renom, Pol; Pérez De La Ossa, Natalia; Terceño, Mikel; Yugueros, Barbara; Ustrell, Xavier; Purroy, Francisco; Rodríguez-campello, Ana; Molina, Carlos; Krupinski, Jerzy; Figueras Aguirre, Georgina; Baraldes, Mariona; Jiménez-fàbrega, Xavier; Salvat-plana, Mercè; Elosua, Roberto; Abilleira, Sonia; Cardona, Pere; Gómez-choco, Manuel
Background and Purpose: The management of patients with anterior circulation large vessel occlusion (LVO) presenting with mild neurological symptoms remains a matter of debate. Early neurological deterioration (END) may influence the decision to perform endovascular treatment (EVT); however, evidence regarding its impact on clinical outcomes is limited. Methods: We conducted a retrospective analysis of prospectively collected data from the Catalan Stroke Registry (2016-2021). Patients with anterior circulation LVO, baseline NIHSS <= 5, baseline mRS score 0-1, and treatment with EVT were included. END was defined as an increase of >= 4 NIHSS points from hospital admission to EVT initiation. Proximal occlusion was defined as occlusion of the extracranial or terminal internal carotid artery or the M1 segment of the middle cerebral artery. The primary outcome was excellent functional outcome at 90 days (mRS 0-1). Good functional outcome (mRS 0-2) was considered a secondary outcome. Mortality and symptomatic intracranial hemorrhage were assessed as safety outcomes. Results: Among 244 patients, 58 (23.8%) experienced END before EVT. At 90 days, 131 patients (53.7%) achieved mRS 0-1 and 162 (66.4%) achieved mRS 0-2. Fourteen patients (5.7%) died during follow-up, and 8 (3.3%) experienced symptomatic intracranial hemorrhage. In multivariable analysis, successful recanalization was independently associated with the primary outcome (OR 4.54, 95% CI 1.73-13.83), whereas END before EVT (OR 1.24, 95% CI 0.40-3.98), proximal occlusion (OR 1.37, 95% CI 0.69-2.71), and their interaction (OR 0.42, 95% CI 0.10-1.67) were not independently associated with excellent functional outcome. Conclusions: In this cohort of patients with mild ischemic stroke treated with EVT, END before EVT was not independently associated with functional outcomes, whereas successful recanalization remained the main determinant of excellent recovery. Pending evidence from randomized clinical trials, these findings suggest that close clinical monitoring with rescue EVT may be an appropriate approach in selected patients.
ArticleAn emerging role for synaptic Zn2+ in substance use disorders
(Elsevier, 2026-04) Solis, Oscar; Curry, Fallon P.; Frangos, Zachary J.; Dunne, William; Schoenborn, Ingrid; Lauer, Alyssa; Gomez, Juan L.; Ventriglia, Emilya; Bonaventura, Jordi; Michaelides, Michael
Synaptic zinc (Zn2+) modulates dopamine and glutamate neurotransmission by binding to the dopamine transporter and glutamate receptors. Among other neurotransmitters, dopamine and glutamate critically regulate physiological processes and behaviors relevant to substance use disorders (SUDs) and addiction. In addition, Zn2+ interacts with inhibitory neurotransmitter systems, including GABA and glycine receptors, further influencing the excitatory-inhibitory balance within circuits relevant to addiction. Nevertheless, the specific involvement of synaptic Zn2+ in such processes is unknown. We propose that synaptic Zn2+ serves as an environmentally derived factor that can influence the vulnerability to and development of SUDs and addiction via its interaction with proteins that regulate dopamine and glutamate neurotransmission in addiction-relevant brain circuits.